Search for a clinical trial
Other search option(s)
8 Result(s)
Recruiting trial
= 
; Ongoing trial
= 
; Funded by an IRDiRC member = 
; Member of a ERN = 
National clinical trial(s)
BELGIUM
VLAAMS BRABANT
LEUVEN
International, Multi-center, Open Label, 9-month Follow-up Extension Study Assessing the Long-term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A - BE
UZ Leuven - Campus Gasthuisberg
Dienst neurologie/ Department of Neurology
FRANCE
ILE-DE-FRANCE
CRÉTEIL
SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study (Phase I-II)
Hôpitaux Universitaires Henri Mondor
Service de neurologie
FRANCE
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE
International, multi-center, randomized, double-blind, placebo-controlled phase III study assessing in parallel groups the efficacy and safety of 2 doses of PXT3003 in patients with Charcot-Marie-Tooth disease type 1A treated 15 months (PLEO-CMT) - FR
CHU de Marseille - Hôpital de la Timone
Service de Neurologie - Maladies neuromusculaires et SLA
SPAIN
Comunidad Valenciana
VALENCIA
PLEO-CMT-FU: International, multi-center, double blind 9-month FOLLOW-UP extension study assessing the long term safety and tolerability of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A - ES
Hospital Universitario y Politécnico La Fe
Servicio de Neurología
SPAIN
Madrid
ADDRESS: NOT PROVIDED - ES
PREMIER: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth type 1A (CMT1A) - ES
Institution: Information not provided - ES
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US
International, Multi-center, Open Label, 9-month Follow-up Extension Study Assessing the Long-term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A -GB
Institution: Information not provided - US
Multinational clinical trial(s)
UNITED KINGDOM
Cambridgeshire
CAMBRIDGE
An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) Previously Enrolled in Study A083-02 and in Patients With Charcot-Marie Tooth (CMT) Disease Types 1 and X Previously Enrolled in Study A083-03
Acceleron Pharma. Inc
Acceleron Pharma
UNITED STATES
Washington
ADDRESS: NOT PROVIDED - US